1 which showed that rosuvastatin significantly reduced cardiovascular events in patients with elevated levels of C-reactive protein. However, broad application of their results in primary prevention is premature, since the baseline therapy that many patients in the study were receiving did not meet existing standards. Although about 50% of the patients had intermediate Framingham risk scores, which would have qualified such men (and possibly women) for aspirin therapy, 2,3 only 16.6% of the patients were receiving aspirin. One quarter of the patients had a systolic blood pressure of at least 145 mm Hg, indicating that their hypertension was not being treated according to existing national goals. 4 Almost 16% of the patients were current smokers.
Although Ridker et al. state that "by design, the study population was diverse," no Asian countries are included among the study sites, and the demographic breakdown of the 17,802 patients according to race or ethnic group includes only white, black, Hispanic, and "other or unknown." It would appear that there may have been a conscious choice to exclude people of Asian descent from JUPITER. Adriane Fugh-Berman, M.D. To the Editor: Although the JUPITER study investigators report event rates for most individual components of the primary end point (nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina, and revascularization), they do not report event rates for death from cardiovascular causes, even though the trial was terminated early in part because of apparent mortality benefits. We therefore attempted to calculate the rates of death from both cardiovascular and noncardiovascular causes from the numbers provided in the article. On the basis of our calculations, in the rosuvastatin group, as compared with the placebo group, the number of deaths from cardiovascular causes was not significantly reduced (31 vs. 37 deaths), although the number of deaths from any cause was significantly reduced (167 vs. 210 deaths). This finding is at odds with extensive data from previous statin trials. In addition, the authors suggest that their results support treating patients on the basis of elevations in C-reactive protein. However, they provide no results showing that C-reactive protein is an independent predictor of the relative or absolute benefit of therapy, since the treatment effects seen with rosuvastatin could have been mediated by reductions in low-density lipoprotein (LDL) cholesterol. Multivariable models that adjust for baseline levels of LDL cholesterol and changes in LDL cholesterol over time would further clarify the role of C-reactive protein. To the Editor: Ridker et al. describe a modest but significant benefit from rosuvastatin, as compared with placebo, in a large group of patients with LDL cholesterol levels of less than 130 mg per deciliter (3.4 mmol per liter) and high-sensitivity C-reactive protein levels of 2 mg per liter or more. Although they state that there was no heterogeneity of results for subgroups of patients according to sex, race or ethnic group, or known coronary risk factors, they did not make a similar statement regarding subgroups stratified according to the baseline level of high-sensitivity C-reactive protein or cholesterol, the very measures that are affected by the study intervention.
Could the authors provide data showing whether there was a gradient of risk for cardiovascular events and death according to baseline levels of C-reactive protein or a gradient of benefit from rosuvastatin according to the extent of the baseline elevation? Furthermore, could they reassure clinicians that there was no incremental risk among patients with the lowest baseline cholesterol levels who were treated with a lipid-lowering statin? Was the clinical benefit explained by changes in levels of C-reactive protein, and how could clinicians monitor the intervention in practice in order to achieve a clinical benefit? Elizabeth R. Jenny-Avital, M.D.
plexing, particularly since the two conditions are believed to share a common inflammatory basis. 1 We therefore used the available published data from large-scale, placebo-controlled trials of statins to evaluate the relationship between statin therapy and incident diabetes.
Among 59,006 patients, the risk of diabetes for patients receiving a statin was similar to that for patients receiving placebo (relative risk, 1.06; 95% CI, 0.91 to 1.23). The risk of diabetes appears to increase with increased potency of the lipidlowering agent. For the two large, placebo-controlled trials of pravastatin, the West of Scotland Coronary Prevention Study (WOSCOPS) and the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study, the relative risk of diabetes in the pravastatin group was 0.81 (95% CI, 0.64 to 1.02). For the two large, placebo-controlled trials of rosuvastatin, JUPITER and the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA), the relative risk of diabetes in the rosuvastatin group was 1.22 (95% CI, 1.05 to 1.42). To the Editor: JUPITER was stopped early, after a median follow-up of 1.9 years. The number of patients who would need to be treated for 2 years to prevent the occurrence of one primary end point was 95. Ridker et al. extrapolate these results by a projection over a 5-year treatment period. This estimation should be viewed critically, since the study has most of the characteristics of a truncated trial.
The majority of randomized clinical trials that are stopped early because of an observed benefit of the treatment under investigation are industryfunded drug trials that are stopped at the first interim analysis, with the results published in a high-impact medical journal. The hazard ratio of 0.56 for the primary end point in JUPITER is close to the median risk ratio of 0.53 among 143 truncated randomized trials. To the Editor: JUPITER was designed to continue until 520 confirmed primary end points had been documented. The study was terminated early because of the efficacy of rosuvastatin. However, the statistical results are reported as if the trial had been designed as a fixed-length trial with 393 primary end points, even though the analysis was sequential. This leads to bias in the reporting. The correct P value for the sequential analysis, as conducted, is P<0.05, not P<0.00001, as reported. In addition, the point estimate of the treatment effect from a trial that was terminated early for efficacy is biased in favor of the treatment. 1 Thus, although it can be agreed that rosuvastatin lowered the risk of cardiovascular disease in this study, the methods used to report the results overestimate the strength of the association. To the Editor: Ridker et al. used conventional Kaplan-Meier analyses to describe the probability of the occurrence of major cardiovascular events over time. Such analyses assume that the event of interest is as likely to occur in the future in patients for whom data have been censored as in those remaining in the trial. This assumption is obviously not the case for patients who died from noncardiovascular causes. The censoring of "competing deaths" estimates the actuarial rather than the actual cumulative incidence. [1] [2] [3] Hence, the absolute difference in risk is inflated, and the respective number of patients who would need to be treated to prevent one occurrence of the end point becomes too low. If we assume that there was a 30% relative overestimation 3 of the actual cumulative incidence, the number needed to treat increases by the same magnitude, from 95 to 124. Since the number of competing deaths from noncardiovascular causes might increase with time, the difference may particularly affect the projected numbers needed to treat at 4 and 5 years. A competing-risk method would have been preferable to determine the actual cumulative incidence and estimates of the number who would need to be treated. component required for proof. Although the formal statistical boundary was conservative and evaluated only after accrual of ample data, the board elected to continue the trial for an additional 6 months after the boundary was crossed. Data that were accrued thereafter independently confirmed both the magnitude and statistical significance of the apparent benefit. We thus respectfully disagree with Pierard and Davis. The board appropriately protected the interests of society and the trial participants and provided a valid estimate of the treatment effect. 4 The evaluation by Koller et al. ignores the significant reduction in death from any cause that we observed. If death from any cause is added to our primary composite outcome (a standard approach to account for competing risks), then the absolute risk difference increases and the number needed to treat declines.
